Skip to main content
Verastem, Inc. logo

Verastem, Inc. — Investor Relations & Filings

Ticker · VSTM ISIN · US92337C2035 LEI · 549300IY0EFBIU8NQC81 US Manufacturing
Open in API
Filings indexed 1,003 across all filing types
Latest filing 2026-05-29 Share Issue/Capital Cha…
Country US United States of America
Listing US VSTM

About Verastem, Inc.

https://www.verastem.com/

Verastem, Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for cancer patients. The company concentrates on targeting the RAS/MAPK signaling pathway, which is associated with numerous aggressive and recurrent cancers. Its clinical program utilizes novel small molecule inhibitors and combination therapies. Verastem has achieved a significant milestone with the FDA approval of its combination therapy, the first treatment specifically for patients with recurrent low-grade serous ovarian cancer (LGSOC) harboring a KRAS mutation. The company's mission is to address urgent medical needs by developing innovative treatments for cancers driven by the RAS/MAPK pathway.

Recent filings

Filing Released Lang Actions
FORM S-8
Share Issue/Capital Change Classification · 89% confidence The document is a Form S-8 registration statement filed with the SEC to register additional shares under the company’s employee equity plans. This is not an Annual Report, earnings release, management change, or regulatory announcement, but rather a share registration that alters the company’s capital structure. Under the filing definitions, this falls under Share Issue/Capital Change (Code: SHA).
2026-05-29 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a Form 8-K reporting Item 5.07 “Submission of Matters to a Vote of Security Holders,” which details the vote counts for director elections, equity plan approvals, auditor ratification, and executive compensation advisory vote at the 2026 annual meeting. This is an official declaration of voting results from a shareholder meeting, matching the Declaration of Voting Results & Voting Rights Announcements category (Code: DVA).
2026-05-26 English
4 - Verastem, Inc. (0001526119) (Issuer)
Director's Dealing
2026-03-23 English
8-K - VERASTEM, INC. (0001526119) (Filer)
Investor Presentation Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate updates. The text specifically mentions "Item 7.01 Regulation FD Disclosure" and states that the company posted an updated corporate presentation on its website, furnished as Exhibit 99.1. The document does not contain detailed financial statements or substantive financial data but rather provides a corporate presentation as an exhibit. The length of the document is 3418 characters, which is relatively short and consistent with an announcement rather than a full report. According to the classification rules, a Form 8-K with a corporate presentation exhibit is best classified as an Investor Presentation (IP).
2026-03-04 English
10-K - VERASTEM, INC. (0001526119) (Filer)
Annual Report FY 2025
2026-03-04 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.